Apellis Pharmaceuticals マネジメント

マネジメント基準チェック /24

Apellis Pharmaceuticalsの CEO はCedric Francoisで、 Sep2009年に任命され、の在任期間は 15.33年です。の年間総報酬は$ 10.37Mで、 7.1%給与と92.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.41%を直接所有しており、その価値は€ 49.98M 。経営陣と取締役会の平均在任期間はそれぞれ5.9年と9.5年です。

主要情報

Cedric Francois

最高経営責任者

US$10.4m

報酬総額

CEO給与比率	7.1%
CEO在任期間	15.3yrs
CEOの所有権	1.4%
経営陣の平均在職期間	5.9yrs
取締役会の平均在任期間	9.5yrs

経営陣の近況

Recent updates

CEO報酬分析

Apellis Pharmaceuticals の収益と比較して、Cedric Francois の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$250m
Jun 30 2024	n/a	n/a	-US$333m
Mar 31 2024	n/a	n/a	-US$417m
Dec 31 2023	US$10m	US$735k	-US$529m
Sep 30 2023	n/a	n/a	-US$606m
Jun 30 2023	n/a	n/a	-US$657m
Mar 31 2023	n/a	n/a	-US$691m
Dec 31 2022	US$9m	US$681k	-US$652m
Sep 30 2022	n/a	n/a	-US$634m
Jun 30 2022	n/a	n/a	-US$638m
Mar 31 2022	n/a	n/a	-US$702m
Dec 31 2021	US$9m	US$647k	-US$746m
Sep 30 2021	n/a	n/a	-US$520m
Jun 30 2021	n/a	n/a	-US$460m
Mar 31 2021	n/a	n/a	-US$360m
Dec 31 2020	US$9m	US$619k	-US$345m
Sep 30 2020	n/a	n/a	-US$536m
Jun 30 2020	n/a	n/a	-US$470m
Mar 31 2020	n/a	n/a	-US$423m
Dec 31 2019	US$4m	US$560k	-US$305m
Sep 30 2019	n/a	n/a	-US$228m
Jun 30 2019	n/a	n/a	-US$194m
Mar 31 2019	n/a	n/a	-US$156m
Dec 31 2018	US$4m	US$550k	-US$128m

報酬と市場: Cedricの総報酬 ($USD 10.37M ) は、 German市場 ($USD 2.08M ) の同規模の企業の平均を上回っています。

報酬と収益: Cedricの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Cedric Francois (52 yo)

15.3yrs

在職期間

US$10,373,049

報酬

Dr. Cedric Francois, M.D., Ph.D. serves as Principal of Vista Therapeutics, Inc. Dr. Francois co-founded Apellis Pharmaceuticals, Inc. in 2009 and has been its Chief Executive Officer, President and Direct...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Cedric Francois	Co-Founder	15.3yrs	US$10.37m	1.41% € 50.0m
Alec Machiels	Co-Founder & Director	16yrs	US$495.96k	0.63% € 22.4m
Timothy Sullivan	CFO & Treasurer	7.3yrs	US$3.74m	0.099% € 3.5m
Adam Townsend	Chief Operating Officer	1yr	US$3.71m	0.034% € 1.2m
David Watson	General Counsel	11yrs	US$4.89m	0.10% € 3.7m
Caroline Baumal	Chief Medical Officer	2yrs	US$4.43m	0.014% € 481.6k
Pascal Deschatelets	Co-Founder & Chief Scientific Officer	15.3yrs	US$3.08m	0.90% € 32.0m
James Chopas	VP, Corporate Controller & Chief Accounting Officer	3.4yrs	データなし	0.014% € 507.9k
Meredith Kaya	Senior Vice President	no data	データなし	データなし
Karen Lewis	Chief People Officer	4.7yrs	データなし	0.012% € 437.5k
Peter Hillmen	Head of Hematology Engagement & Member of PNH Scientific Advisory Board	2.7yrs	データなし	データなし
Victoria Brown	Senior Vice President	5.9yrs	データなし	データなし

5.9yrs

平均在職期間

51.5yo

平均年齢

経験豊富な経営陣: 1JKの経営陣は経験豊富で経験豊富です（平均在職期間は5.9年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Cedric Francois	Co-Founder	15.3yrs	US$10.37m	1.41% € 50.0m
Alec Machiels	Co-Founder & Director	15.3yrs	US$495.96k	0.63% € 22.4m
Peter Hillmen	Head of Hematology Engagement & Member of PNH Scientific Advisory Board	9.5yrs	データなし	データなし
Lokchung L. Chan	Independent Chairman of the Board	11.5yrs	US$504.08k	0.014% € 506.1k
Stephanie O'Brien	Independent Director	11.5yrs	US$488.46k	0.014% € 506.1k
Gabriel Coscas	Member of AMD Scientific Advisory Board	9.5yrs	データなし	データなし
Robert Brodsky	Member of PNH Scientific Advisory Board	9.5yrs	データなし	データなし
Michael Yeadon	Member of Pulmonology Scientific Advisory Board	9.5yrs	データなし	データなし
Paul Fonteyne	Independent Director	4.8yrs	US$489.08k	0.0046% € 162.2k
A. Dunlop	Independent Director	14.8yrs	US$480.96k	0.12% € 4.3m
Marsha Wills-Karp	Member of Pulmonology Scientific Advisory Board	no data	データなし	データなし
Carl Atkinson	Member of Pulmonology Scientific Advisory Board	9.5yrs	データなし	データなし

9.5yrs

平均在職期間

57.5yo

平均年齢

経験豊富なボード: 1JKの取締役会は経験豊富であると考えられます ( 9.5年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/01/26 07:28
終値	2025/01/24 00:00
収益	2024/09/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Apellis Pharmaceuticals, Inc. 21 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。34

アナリスト	機関
Colleen Kusy	Baird
Michael Ulz	Baird
Ishan Majumdar	Baptista Research

Apellis Pharmaceuticals マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Apellis Pharmaceuticals, Inc. Announces Executive Changes

Apellis Pharmaceuticals Appoints Keli Walbert to the Board of Directors

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Chief Technical Operations Officer recently sold €590k worth of stock

Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024

Apellis Pharmaceuticals, Inc. Appoints Adam Townsend as Chief Operating Officer

Recent updates

Apellis Pharmaceuticals, Inc. Announces Executive Changes

Apellis Pharmaceuticals Appoints Keli Walbert to the Board of Directors

Third quarter 2024 earnings released: US$0.46 loss per share (vs US$1.17 loss in 3Q 2023)

Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study

Apellis Pharmaceuticals, Inc. Presents Positive Results from the Phase 3 VALIANT Study at Kidney Week

Forecast breakeven date pushed back to 2026

Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN

Forecast to breakeven in 2025

Second quarter 2024 earnings released: US$0.30 loss per share (vs US$1.02 loss in 2Q 2023)

Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

First quarter 2024 earnings released: US$0.54 loss per share (vs US$1.56 loss in 1Q 2023)

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency

Chief Technical Operations Officer recently sold €590k worth of stock

Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024

Full year 2023 earnings released: US$4.45 loss per share (vs US$6.15 loss in FY 2022)

Apellis Pharmaceuticals, Inc. Announces Negative CHMP Opinion for Pegcetacoplan for Ga in the European Union and Plans to Seek Re-Examination of Application

Apellis Pharmaceuticals, Inc. Appoints Adam Townsend as Chief Operating Officer

Co-Founder recently sold €482k worth of stock

Apellis Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

Apellis Pharmaceuticals, Inc. and Sobi Presents Post Hoc Data that Reinforce the Long-Term Efficacy and Safety of EMPAVELI

Insufficient new directors

Apellis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Apellis Pharmaceuticals, Inc. Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration

Apellis Pharmaceuticals, Inc. Receives Permanent J-Code (J2781) for SYFOVRE® (Pegcetacoplan Injection), Effective October 1, 2023

Levi & Korsinsky, LLP Notifies Investors in Apellis Pharmaceuticals, Inc. of Class Action Securities Lawsuit

Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI

Apellis Pharmaceuticals, Inc. Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE (Pegcetacoplan Injection)

Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Files Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc

No longer forecast to breakeven

Second quarter 2023 earnings released: US$1.02 loss per share (vs US$1.46 loss in 2Q 2022)

Apellis Pharmaceuticals, Inc. Provides Update on Review of Rare Safety Events with SYFOVRE® for Geographic Atrophy

Insufficient new directors

FDA Approves Syfovre (Pegcetacoplan Injection) as the First and Only Treatment for Geographic Atrophy (GA)

Apellis Appoints Retina Specialist Dr. Caroline Baumal as Chief Medical Officer

Forecast to breakeven in 2025

Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)

Insufficient new directors

Apellis Pharmaceuticals, Inc. Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy

Apellis Pharmaceuticals, Inc. Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting

Apellis Pharmaceuticals, Inc. Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy

Apellis Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of Geographic Atrophy

Apellis Pharmaceuticals, Inc. Announces Five Oral Presentations in Geographic Atrophy Highlighted at the ASRS Annual Scientific Meeting

Insider recently sold €116k worth of stock

Apellis Pharmaceuticals, Inc. and Sobi(R) Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress

Apellis Pharmaceuticals, Inc. and Sobi Announces First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need

Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy

No longer forecast to breakeven

Apellis Pharmaceuticals, Inc. Announces Appointment of Peter Hillmen as Head of Hematology Engagement, Effective May 23, 2022

Apellis Pharmaceuticals, Inc. Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy at ARVO Annual Meeting

Insufficient new directors

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2022

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

General Counsel recently sold €51k worth of stock

Forecast to breakeven in 2024

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Announce EU Approval of Aspaveli® (Pegcetacoplan) for Treatment of PNH

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) Report Empaveli™ Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population

Apellis Announces Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Report Positive Top-Line Results from the Phase 3 Prince Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH

Apellis Announces U.S. Food and Drug Administration (Fda) Approval of Empaveli™ (Pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

ApApellis Pharmaceuticals, Inc. to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association Virtual Congress

The NEJM Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH

Apellis Pharmaceuticals, Inc. Provides Update on APL-9 for Severe COVID-19

New 90-day high: €46.60

Apellis Pharmaceuticals, Inc. Enters into A Commercial Supply Agreement with Bachem Americas, Inc

New 90-day high: €45.40

Swedish Orphan Biovitrum AB and Apellis Pharmaceuticals Inc. Reports Positive Top-Line Results At 48 Weeks from the Phase 3 Pegasus Study of Pegcetacoplan in PNH

マネジメント基準チェック /24